Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
24
Recruiting, any sponsor type, condition "geographic atrophy"
By trial status
The same filters, counted in each status. Pick one to switch.
24 trials
Showing 1 to 24, recently updated first.
- A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationPivotal-lookingRecruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07851259 · 321 participants (planned) · Start Jan 8, 2027 · Primary completion Aug 21, 2030
Drug: RO7965032; Placebo · For: Geographic Atrophy Secondary to Age-Related Macular Degeneration
Sites: Walnut Creek, California; Biloxi, Mississippi; Winston-Salem, North Carolina · 9 sites in all
Astellas Institute for Regenerative MedicineAstellas (ALPMY)
NCT03178149 · 42 participants (planned) · Start Jan 30, 2019 · Primary completion Dec 31, 2027
Drug: ASP7317; tacrolimus and 3 more · For: Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Los Angeles, California; Palo Alto, California · 20 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT05626114 · 60 participants (planned) · Start Mar 23, 2023 · Primary completion Mar 1, 2031
Drug: OpRegen · For: Geographic Atrophy
Sites: Beverly Hills, California; Sacramento, California; San Francisco, California · 17 sites in all
The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
NCT07418177 · 12 participants (planned) · Start Oct 14, 2025 · Primary completion Dec 31, 2028
Drug: hiPSC-RPEs · For: AMD - Age-Related Macular Degeneration
Sites: Nanjing, China
- Phase 2 Study of ADX-038 in Participants With Geographic AtrophyPivotal-lookingRecruiting
ADARx Pharmaceuticals, Inc.Industry
NCT06990269 · 240 participants (planned) · Start Nov 10, 2025 · Primary completion Feb 28, 2030
Drug: ADX-038; Placebo · For: Geographic Atrophy Secondary to Age-related Macular Degeneration
Sites: Gilbert, Arizona; Phoenix, Arizona; Bakersfield, California · 83 sites in all
National Eye Institute (NEI)NIH
NCT04339764 · 20 participants (planned) · Start Sep 23, 2020 · Primary completion May 31, 2029
Drug: iPSC-derived RPE/PLGA transplantation · For: Dry Age-Related Macular Degeneration; Geographic Atrophy
Sites: Baltimore, Maryland; Bethesda, Maryland
- A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMDPivotal-lookingRecruiting
Galimedix Therapeutics IncIndustry
NCT06659549 · 110 participants (planned) · Start Jan 10, 2025 · Primary completion Mar 30, 2028
Drug: GAL-101; Placebo · For: Geographic Atrophy of the Macula
Sites: Beverly Hills, California; Walnut Creek, California; Hagerstown, Maryland · 24 sites in all
- A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07441642 · 272 participants (planned) · Start Mar 9, 2026 · Primary completion Aug 21, 2029
Drug: FWY003; Placebo · For: Geographic Atrophy Secondary to Age-related Macular Degeneration
Sites: Huntington Beach, California; Sacramento, California; Santa Barbara, California · 65 sites in all
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06541704 · 975 participants (planned) · Start Oct 30, 2024 · Primary completion Jul 31, 2028
Drug: Pozelimab; Cemdisiran and 1 more · For: Age-related Macular Degeneration (AMD); Geographic Atrophy (GA)
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 233 sites in all
- A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)Pivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06635148 · 274 participants (planned) · Start Sep 19, 2024 · Primary completion Aug 24, 2029
Drug: JNJ-81201887 · For: Geographic Atrophy; Macular Degeneration
Sites: Tucson, Arizona; Fullerton, California; La Jolla, California · 104 sites in all
Cellio Therapeutics IncIndustry
NCT07594236 · 15 participants (planned) · Start Apr 7, 2026 · Primary completion Dec 31, 2028
Drug: Injection · For: Geographic Atrophy; Stargardt Disease; RPE-mediated Maculopathy and 1 more
Sites: Beverly Hills, California; Palo Alto, California; Sacramento, California
- A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07215234 · 104 participants (planned) · Start Oct 9, 2025 · Primary completion Oct 13, 2027
Drug: SAR446597; Sham Comparator · For: Geographic Atrophy
Sites: Peoria, Arizona; Scottsdale, Arizona; Beverly Hills, California · 35 sites in all
- A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular DegenerationPivotal-lookingRecruiting
Biojiva LLCIndustry
NCT07029945 · 152 participants (planned) · Start Sep 29, 2026 · Primary completion Apr 2029
Drug: BRX011; Placebo · For: Geographic Atrophy
Sites: Gilbert, Arizona; Phoenix, Arizona; Hattiesburg, Mississippi · 17 sites in all
- A Study in Adults With Geographic AtrophyPivotal-lookingRecruiting
Sitala Bio LTDIndustry
NCT07606365 · 300 participants (planned) · Start Sep 11, 2026 · Primary completion Jul 2028
Drug: STL303; Placebo · For: Geographic Atrophy
Sites: Bakersfield, California; Beverly Hills, California; Aurora, Colorado · 56 sites in all
- Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMDPivotal-lookingRecruiting
ONL TherapeuticsIndustry
NCT06659445 · 324 participants (planned) · Start Oct 28, 2025 · Primary completion Nov 2028
Drug: ONL1204 Opthalmic solution; Avacincaptad Pegol intravitreal solution · For: Geographic Atrophy (GA); Age - Related Macular Degeneration (AMD)
Sites: Gilbert, Arizona; Phoenix, Arizona; Bakersfield, California · 120 sites in all
- SGLT2 Inhibitors in Geographic AtrophyRecruiting
Washington University School of MedicineAcademic, hospital or other
NCT07174687 · 70 participants (planned) · Start Dec 2, 2025 · Primary completion Dec 2027
Drug: Dapagliflozin · For: Retinal Degeneration; Retinal Diseases; Eye Diseases and 2 more
Sites: St Louis, Missouri
- Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMDPivotal-lookingRecruiting
OcugenIndustry
NCT07770828 · 237 participants (planned) · Start Aug 11, 2026 · Primary completion Jul 30, 2028
Drug: OCU410 · For: Dry Age-related Macular Degeneration
Sites: Phoenix, Arizona; Erie, Pennsylvania; McAllen, Texas
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07230834 · 54 participants (planned) · Start Jan 19, 2026 · Primary completion Jul 3, 2028
Drug: Pozelimab · For: Geographic Atrophy (GA)
Sites: Lakewood, Colorado; East Weymouth, Massachusetts; Austin, Texas · 9 sites in all
AbbVieAbbVie (ABBV)
NCT07160179 · 66 participants (planned) · Start Aug 13, 2025 · Primary completion Oct 2029
Drug: ABBV-6628; SYFOVRE · For: Geographic Atrophy; Age-Related Macular Degeneration
Sites: Carmel, Indiana; Reno, Nevada; Abilene, Texas · 5 sites in all
Theratocular Biotek Co.Industry
NCT07668804 · 31 participants (planned) · Start Jun 2, 2026 · Primary completion Aug 31, 2027
Drug: TO-O-1007 (low-dose); TO-O-1007 (high-dose) · For: Geographic Atrophy Due to Age-Related Macular Degeneration
Sites: Hurstville, Australia; Sydney, Australia; Launceston, Australia
Apellis Pharmaceuticals, Inc.Industry
NCT07215390 · 240 participants (planned) · Start Jun 23, 2025 · Primary completion Jun 25, 2027
Drug: APL-3007, pegcetacoplan (APL-2); APL-3007, pegcetacoplan (APL-2) · For: Geographic Atrophy Secondary to Age-related Macular Degeneration
Sites: Gilbert, Arizona; Mesa, Arizona; Phoenix, Arizona · 78 sites in all
- Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic AtrophyRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT04292080 · 90 participants (planned) · Start Feb 7, 2022 · Primary completion Apr 7, 2027
Drug: Dimethyl Fumarate (TECFIDERA™) · For: Age-related Macular Degeneration (AMD)
Sites: Créteil, France
Bionic Sight LLCIndustry
NCT07158775 · 40 participants (planned) · Start Jan 8, 2026 · Primary completion Dec 2027
Drug: BS01 · For: Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Sites: Edison, New Jersey
Eyestem Research Pvt. Ltd.Industry
NCT06394232 · 54 participants (planned) · Start Jun 4, 2024 · Primary completion Apr 2025
Drug: Eyecyte-RPE™ · For: Retinal Disease; Macular Degeneration; Age-Related Macular Degeneration and 2 more
Sites: Jālna, India; Delhi, India; Hyderabad, India
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.